Drug Type Antibody drug conjugate (ADC) |
Synonyms MBRC 201, MBRC201 |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Breast Cancer | Phase 2 | United States | 03 Sep 2025 | |
| Colorectal Cancer | Phase 2 | United States | 03 Sep 2025 | |
| Non-Small Cell Lung Cancer | Phase 2 | United States | 03 Sep 2025 | |
| Pancreatic Ductal Adenocarcinoma | Phase 2 | United States | 03 Sep 2025 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | United States | 01 Sep 2025 | |
| Metastatic castration-resistant prostate cancer | Phase 2 | United States | 01 Sep 2025 | |
| Metastatic Solid Tumor | Phase 2 | United States | 01 Sep 2025 | |
| Hematologic Neoplasms | Preclinical | United States | 24 Jul 2024 |






